Activity profile of tigecycline and comparator agents against skin and wound isolates collected across Europe, 20062009
Abstract number: P928
Objective: TIG was approved in 2006 for the treatment of complicated skin and skin structure infections. The spectrum of activity of TIG includes both Gram-positive and Gram-negative pathogens, including those with commonly encountered resistance phenotypes. It is important to continue to monitor the activity of commonly utilized agents, in particular recently approved agents, for resistance among targeted pathogens. This study reports the current activity profile of TIG and comparators against recent Gram-positive and Gram-negative pathogens collected in Europe focusing on skin and wound isolates.
Methods: 955 skin/wound and 2299 non-skin/wound Gram-positive and Gram-negative organisms collected from 20062009 were centrally tested by broth microdilution (CLSI M7-A8). Isolates were obtained from sites distributed across 12 European countries. EUCAST breakpoints (BP) were used to interpret TIG MIC results and CLSI (M100-S19) BP were used to interpret all other agents.
Results: Against Gram-positive skin/wound isolates consisting of S. aureus (including MRSA), group A streptococci (GAS), and vancomycin susceptible E. faecalis (VSE), TIG displayed potent in vitro activity with MIC50s of 0.03 mg/L (GAS) and 0.12 mg/L (MSSA/MRSA/VSE) and MIC90s of 0.06 mg/L (GAS) and 0.25 mg/L (MSSA/MRSA/VSE), several fold lower than evaluated comparators. Over 99% of Gram-positive skin and wound isolates were susceptible to TIG and to other Gram-positive agents (linezolid, daptomycin, vancomycin). TIG was also potent against Gram-negative enteric skin/wound isolates, with MIC50s ranging from 0.12 to 0.5 mg/L and MIC90s from 0.5 to 1 mg/L. No TIG resistance was detected among skin/wound isolates across the evaluated Enterobacteriaceae spp., as was the case with imipenem. In contrast, resistance was readily detected at varying levels among the evaluated cephalosporins, gentamicin, ciprofloxacin, and piperacillin/tazobactam. There was no notable difference in TIG activity profile between that observed with skin/wound isolates and non-skin/wound isolates.
Conclusions: TIG was potent against both Gram-positive and Gram-negative skin/wound pathogens in Europe. Excluding S. aureus where <1% of isolates were TIG resistant, no TIG was observed among the evaluated isolates. The broad spectrum potency and overall lack of resistance highlights the therapeutic potential of TIG, however continued surveillance is warranted to monitor for emerging resistance among primary pathogens.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|